Inflection Biosciences
Business Services · Ireland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Anglesea House Carysfort Ave Ste 15, Bla...Phone Number
(857) 529-5480Website
www.inflectionbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inflection Biosciences
Inflection Biosciences Ltd is an early-stage drug development company focused on discovering and developing innovative small molecule therapeutics for cancer, autoimmune, and inflammatory diseases. Their pipeline includes IBL-202, a dual mechanism kinase inhibitor, and AUM302, partnered with AUM Biosciences. The company aims to address major unmet needs in these therapeutic areas. Inflection Biosciences is dedicated to advancing its innovative therapeutics through rigorous research and development.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inflection Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Inflection Biosciences had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Inflection Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Inflection Biosciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Inflection Biosciences launches new products
Inflection Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Inflection Biosciences has new funding data
Congratulate Masked Content for being promoted to Masked Content at Inflection Biosciences
Check out if Inflection Biosciences is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Inflection Biosciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Inflection Biosciences
Compare insights from companies similar to Inflection Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Inflection Biosciences
<$5M
11-50
Private
<$5M
2012
N/A
Company Profile Activity
Activity Insights
Inflection Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Inflection Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Inflection Biosciences.
Inflection Biosciences financials insights
Gather financial insights about Inflection Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$785K
Inflection Biosciences Tech Stack
A closer look at the technologies used by Inflection Biosciences
Inflection Biosciences News & Media
Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors
DUBLIN--(BUSINESS WIRE)--Inflection Biosciences and AUM Biosciences announce Global License Agreement for PIM/PI3K/mTOR inhibitorsAUM Biosciences Expands Pipeline With Global License for First-in-class Targeted Cancer Therapy
SINGAPORE--(BUSINESS WIRE)--AUM Biosciences (AUM), an award-winning company focused on the development of innovative and affordable oncology medicines with high unmet medical need in Asia, today announced a global license agreement with Inflection Biosciences (Inflection) for exclusive worldwide rights to develop, manufacture and commercialise Inflection’s first-in-class PIM/PI3K/mTOR inhibitors. Known as the IBL-300 series of molecules, the agreement will see AUM develop the lead candidate, IBInflection Biosciences Announces Research Collaboration with MD Anderson
DUBLIN--(BUSINESS WIRE)--Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today announced a research collaboration with MD AndersonCompany Profile for Inflection Biosciences Ltd
--(BUSINESS WIRE)--Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises the IBL-300 series (PIM/PI3K/mTOR inhibitors) and IBL-202 (PIM/PI3K inhibitor) selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (selective pan-PIM kinase inhibitors)
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inflection Biosciences
Sign Up For FreeTo access detailed company insights
Inflection Biosciences Ltd is an early-stage drug development company focused on discovering and developing innovative small molecule therapeutics for cancer, autoimmune, and inflammatory diseases. Their pipeline includes IBL-202, a dual mechanism kinase inhibitor, and AUM302, partnered with AUM Biosciences. The company aims to address major unmet... Read More
